It wants to get ahead of competitors such as BMS, Merck, Pfizer ... The interaction with GSK goes deeper, with Novartis and GSK announcing a merger of their OTC divisions to create a new joint ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month ... which include GSK’s Haleon spinout and Proctor & Gamble as well as the larger market.

Pfizer and GSK plan to divest the business completely ... and the deal was instantly controversial in both Europe and the US. The merger would have created the biggest pharmaceutical company ...

The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Consumer Health restructuring The merger of GlaxoSmithKline and Pfizer is dragging on sales—up 1 percent in 2019—as the businesses streamline. This compares with a Glaxo consumer ...

It is generally well appreciated that the pharmaceutical industry has entered a period of revenue underperformance. However, the severity of this underperformance, even when measured against ...

Parke-Davis (India) in the near future is unlikely to get five major products which Glaxo Wellcome worldwide ... The operational merger between Pfizer and Parke-Davis has been completed and ...

Moderna, Pfizer, and BioNTech are also developing ... and 11% have gotten this year’s vaccine.GlaxoSmithKline sued Moderna in ...

A total of 739 deals were completed so far this year representing a decrease of just under 21 per cent compared to last year.

he was following in the wake of other large pharmaceutical companies that have spun off consumer health units including GSK Plc, Novartis AG, Pfizer Inc. and Johnson & Johnson, as drugmakers target ...